NON-ALCOHOLIC STEATOHEPATITIS (NASH)
Clinical trials for NON-ALCOHOLIC STEATOHEPATITIS (NASH) explained in plain language.
Never miss a new study
Get alerted when new NON-ALCOHOLIC STEATOHEPATITIS (NASH) trials appear
Sign up with your email to follow new studies for NON-ALCOHOLIC STEATOHEPATITIS (NASH), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
Experimental NASH drug shows early promise in small trial
Disease control CompletedThis study tested a drug called TRO19622 in 22 adults with NASH, a liver condition linked to fat buildup. Participants took either the drug or a placebo daily for one month. The goal was to see if the drug safely lowered liver enzyme levels, which are markers of liver injury. Res…
Matched conditions: NON-ALCOHOLIC STEATOHEPATITIS (NASH)
Phase: PHASE2 • Sponsor: Hoffmann-La Roche • Aim: Disease control
Last updated May 26, 2026 05:06 UTC
-
New pill shows promise against fatty liver disease in Mid-Stage trial
Disease control CompletedThis study tested an experimental drug called HSK31679 in 186 Chinese adults with non-alcoholic steatohepatitis (NASH), a serious fatty liver disease that can lead to scarring. Participants took either 80 mg, 160 mg, or a placebo daily for 52 weeks. The goal was to see if the dru…
Matched conditions: NON-ALCOHOLIC STEATOHEPATITIS (NASH)
Phase: PHASE2 • Sponsor: Haisco Pharmaceutical Group Co., Ltd. • Aim: Disease control
Last updated May 26, 2026 04:34 UTC
-
New drug shows promise against fatty liver and obesity in major trial
Disease control CompletedThis study tested a medicine called survodutide in 218 adults with overweight or obesity and a liver condition called NASH (fatty liver with inflammation). Participants received weekly injections of survodutide or a placebo for about a year, along with diet and exercise advice. T…
Matched conditions: NON-ALCOHOLIC STEATOHEPATITIS (NASH)
Phase: PHASE3 • Sponsor: Boehringer Ingelheim • Aim: Disease control
Last updated May 22, 2026 14:02 UTC
-
New drug shows promise against fatty liver disease in Mid-Stage trial
Disease control CompletedThis study tested a drug called pemvidutide in 212 adults with nonalcoholic steatohepatitis (NASH), a serious fatty liver disease that can lead to scarring. The goal was to see if the drug could reverse liver damage or reduce scarring without making the disease worse. Participant…
Matched conditions: NON-ALCOHOLIC STEATOHEPATITIS (NASH)
Phase: PHASE2 • Sponsor: Altimmune, Inc. • Aim: Disease control
Last updated May 20, 2026 11:54 UTC
-
First human doses of experimental NASH drug given to healthy men
Knowledge-focused CompletedThis study tested a single dose of a new drug called AZD4076 in 40 healthy men to see if it is safe and how the body processes it. The drug is being developed for non-alcoholic steatohepatitis (NASH), a serious liver condition. Since this was a very early (Phase 1) trial in healt…
Matched conditions: NON-ALCOHOLIC STEATOHEPATITIS (NASH)
Phase: PHASE1 • Sponsor: AstraZeneca • Aim: Knowledge-focused
Last updated May 26, 2026 04:37 UTC